Abstract: Comprehensive, accurate, and publicly available HIV-1 antiretroviral (ARV) drug resistance data is essential for population-based monitoring of acquired and transmitted drug resistance in resource-limited regions, for guiding salvage ARV therapy in well-resourced regions, and for identifying overall ARV-development needs. However, the variability of viruses that comprise the HIV-1 pandemic and the high mutation rate of HIV-1 make it difficult to quantify transmitted and acquired drug resistance, to optimally interpret HIV-1 genotypic resistance tests, and to identify those ARV-resistant variants most relevant to the development of future ARVs.

The Stanford HIV Drug Resistance Database (HIVDB) is the only publicly available source for three main data correlations underlying HIV-1 drug resistance knowledge: (1) Correlations between genotypic data for the enzymatic targets of ARV therapy – protease, reverse transcriptase, and integrase – with the ARV treatments of persons from whom the sequenced HIV-1 isolates were obtained; (2) Correlations between genotype and in vitro drug susceptibility; and (3) Correlations between genotype and the virological response to a new ARV treatment regimen. By emphasizing the collection, annotation, dissemination, and analysis of three main types of data, HIVDB facilitates meta-analyses in which data from many published studies and clinical trials can be effectively synthesized.

rshafer-abstract.txt · Last modified: 2012/09/10 08:21 by stuo
Except where otherwise noted, content on this wiki is licensed under the following license:CC Attribution-Noncommercial-Share Alike 3.0 Unported
Recent changes RSS feed Donate Powered by PHP Valid XHTML 1.0 Valid CSS Driven by DokuWiki